TrialThe Lancet. Oncology2024
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Egbert F Smit et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
123 papers cite itlatest 60 shown
this paperpooled ittrialcites it